Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.
beta-amyloid plaques (Abeta plaques) in the brain, containing predominantly fibrillary Abeta peptide aggregates, represent a defining pathologic feature of Alzheimer disease (AD). Imaging agents targeting the Abeta plaques in the living human brain are potentially valuable as biomarkers of pathogenesis processes in AD. (E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine ((18)F-AV-45) is such as an agent currently in phase III clinical studies for PET of Abeta plaques in the brain.


METHODS
In vitro binding of (18)F-AV-45 to Abeta plaques in the postmortem AD brain tissue was evaluated by in vitro binding assay and autoradiography. In vivo biodistribution of (18)F-AV-45 in mice and ex vivo autoradiography of AD transgenic mice (APPswe/PSEN1) with Abeta aggregates in the brain were performed. Small-animal PET of a monkey brain after an intravenous injection of (18)F-AV-45 was evaluated.


RESULTS
(18)F-AV-45 displayed a high binding affinity and specificity to Abeta plaques (K(d), 3.72 +/- 0.30 nM). In vitro autoradiography of postmortem human brain sections showed substantial plaque labeling in AD brains and not in the control brains. Initial high brain uptake and rapid washout from the brain of healthy mice and monkey were observed. Metabolites produced in the blood of healthy mice after an intravenous injection were identified. (18)F-AV-45 displayed excellent binding affinity to Abeta plaques in the AD brain by ex vivo autoradiography in transgenic AD model mice. The results lend support that (18)F-AV-45 may be a useful PET agent for detecting Abeta plaques in the living human brain.
Choi
Seok Rye
SR
Avid Radiopharmaceutical Inc., Philadelphia, Pennsylvania, USA.
Golding
Geoff
G
Zhuang
Zhiping
Z
Zhang
Wei
W
Lim
Nathaniel
N
Hefti
Franz
F
Benedum
Tyler E
TE
Kilbourn
Michael R
MR
Skovronsky
Daniel
D
Kung
Hank F
HF
D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000814:Aniline Compounds / Q000378:metabolism* / Q000493:pharmacokinetics; D000818:Animals; D001345:Autoradiography; D001554:Benzene / Q000378:metabolism* / Q000493:pharmacokinetics; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology*; D005026:Ethylene Glycols / Q000378:metabolism* / Q000493:pharmacokinetics; D005260:Female; D000882:Haplorhini; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D049268:Positron-Emission Tomography; D014018:Tissue Distribution
D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D005026:Ethylene Glycols; C545186:florbetapir; D001554:Benzene